Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data

Area of Science:

• Gerontology
• Pharmacology
• Neurology

Background:

• Arterial hypertension is a known risk factor for cognitive impairment in older adults.
• Previous studies on antihypertensives' effects on cognition have yielded inconsistent results.

Purpose of the Study:

• To investigate the impact of various antihypertensive drug classes on the conversion rate from normal cognition to mild cognitive impairment (MCI).
• To analyze the influence of single and combined antihypertensive therapies on cognitive decline progression.

Main Methods:

• Utilized the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).
• Analyzed the association between different antihypertensive classes and the rate of MCI conversion.
• Assessed the modulating effects of age, gender, and APOE4 genotype.

Main Results:

• Antihypertensive drug use was linked to a 21% delay in MCI conversion (HR: 0.79).
• Calcium channel blockers (CCBs), diuretics, and α1-adrenergic blockers (α1-ABs) significantly delayed MCI onset.
• Specific dihydropyridine CCBs (amlodipine, nifedipine) showed substantial cognitive benefits; certain diuretics and combined therapies (e.g., α1-AB + diuretics) demonstrated synergistic or additive effects.

Conclusions:

• Findings suggest antihypertensives can be strategically used to mitigate cognitive decline in at-risk elderly populations.
• Therapeutic choices for hypertension in older adults should consider potential cognitive benefits, optimizing combination therapies for maximum impact on cognitive function.